利福平作用机制 - Medchemexpress - MCE中国

1、Product Data SheetRifampicinCat. No.: HY-B0272CAS No.: 13292-46-1分式: CHNO分量: 822.94作靶点: Bacterial; Influenza Virus作通路: Anti-infection储存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性数据体外实验 DMSO : 50 mg/mL (60.76 mM; Need ultrasonic)H2O : 0.1 mg/mL (insoluble)SolventMass1 mg 5

2、 mg 10 mgConcentration制备储备液1 mM 1.2152 mL 6.0758 mL 12.1516 mL5 mM 0.2430 mL 1.2152 mL 2.4303 mL10 mM 0.1215 mL 0.6076 mL 1.2152 mL请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；旦配成溶液，请分装保存，避免反复冻融造成的产品失效。储备液的保存式和期限：-80C, 6 months; -20C, 1 month。-80C 储存时，请在 6 个内使，-20C 储存时，请在 1 个内使。体内实验请根据您的实验动物和给药式选择适当的溶解案。以下溶解案都请先按照 I

3、n Vitro 式配制澄清的储备液，再依次添加助溶剂：为保证实验结果的可靠性，澄 的储备液可以根据储存条件，适当保存；体内实验的作液，建议您现现配，当天使； 以下溶剂前显的百分 指该溶剂在您配制终溶液中的体积占；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的式助溶1. 请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.5 mg/mL (3.04 mM); Clear solution; Need ultrasonic此案可获得 2.5 mg/mL (3.04 mM) 的澄清溶液。以 1 mL 作液为

4、例，取 100 L 25.0 mg/mL 的澄 DMSO 储备液加到 400 L PEG300 中，混合均匀；向上述体系中加50 L Tween-80，混合均匀；然后继续加 450 L 理盐定容 1 mL。2. 请依序添加每种溶剂： 10% DMSO 90% (20% SBE-CD in saline)Solubility: 2.5 mg/mL (3.04 mM); Clear solutionPage 1 of 2 www.MedChemE此案可获得 2.5 mg/mL (3.04 mM，饱和度未知) 的澄清溶液。以 1 mL 作液为例，取 100 L 25.0 mg/mL 的澄 DMSO

5、储备液加到 900 L 20% 的 SBE-CD 理盐溶液中，混合均匀。BIOLOGICAL ACTIVITY物活性 Rifampicin种有效的谱抗素，可抵抗细菌病原体。Rifampicin 具有抗流感病毒活性。体外研究 Rifampicin (100 mg/mL) can block the functional activity of P-glycoprotein. Rifampicin is not a substract for P-glycoprotein. The mechanism of rifampicin resistance is unassociated with th

6、e functional activity of P-glycoprotein3.体内研究 Rifampicin (200, 400 mg/kg) can induce fatty liver at high concentration1. Rifampicin (30 mg/kg, i.p.) treatment ofS464P biofilms in vivo results in a slight decline, but earlier rebinds in bioluminescence from these catheterscompared with the parental s

7、ignal, whereas rifampicin has no affect on bioluminescence in mice infected with mutantH481Y2.PROTOCOLAnimal Briefly, 1 cm Teflon catheter (14-gauge) carrying 104 cfu S. aureus, either the parental strain Xen 29 or the RifRAdministration 2 mutants S464P or H481Y, are implanted subcutaneously in grou

8、ps of nine mice per strain. One catheter segment isinserted on each side of each animal. Six days after the implantation of the catheters, five mice from each group aretreated with rifampicin at 30 mg/kg intraperitoneally in 0.1 mL saline, twice daily for four consecutive days. Theremaining four mic

9、e in each group are left untreated as controls. At various time points during the infection, the miceare anaesthetized using a constant flow of 1.5% isoflurane from the IVIS manifold, and imaged using an IVISImage System 100 Series. The bioluminescent signals (photons/s) emitted from the mice are an

10、alysed usingLivingImage software and plotted over the course of infection. The mice are sacrificed 20 days after infection (11days after final rifampicin treatment). The catheters are surgically removed and the bacteria are detached bysonication for determination of bacterial burdens on the catheter

11、s.MCE has not independently confirmed the accuracy of these methods. They are for reference only.户使本产品发表的科研献 Phytomedicine. 2019 Mar 15;56:175-182. RSC Adv. 2019 May. Onco Targets Ther. 2018 Sep 17;11:5885-5894. Xenobiotica. 2019 Feb 11:1-33. Patent. US20200101105A1.See more customer validations on

12、HYPERLINK www.MedChemE www.MedChemEREFERENCES1. Piriou A, et al. Fatty liver induced by high doses of rifampicin in the rat: possible relation with an inhibition of RNA polymerases in eukariotic cells. ArchToxicol Suppl. 1979;(2):333-7.Page 2 of 3 www.MedChemE2. Yu J, et al. Monitoring in vivo fitne

13、ss of rifampicin-resistant Staphylococcus aureus mutants in a mouse biofilm infection model. J Antimicrob Chemother.2005 Apr;55(4):528-34. Epub 2005 Mar 2.3. Erokhina MV, et al. In vitro development of rifampicin resistance in the epithelial cells. Probl Tuberk Bolezn Legk. 2006;(8):58-61.4. Hamzehei M, et al. Inhibition of influenza A virus replication by rifampicin and selenocystamine. J Med Virol. 1980;6(2):169-74.McePdfHeightCaution: